RecruitingPhase 4NCT05730205
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
Sponsor
University of Pennsylvania
Enrollment
22 participants
Start Date
Jun 8, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Nexplanon 68 MG Drug Implant for people with sickle cell disease. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNexplanon 68 MG Drug Implant
Progestin contraceptive device
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05730205
Related Trials
Uganda Sickle Surveillance Study (US-3)
NCT063018934 locations
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
NCT075991761 location
Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)
NCT053839111 location
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT039378171 location
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226105 locations